2626 related articles for article (PubMed ID: 32920628)
1. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
2. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis.
Wang HY; Lee KC; Pei Z; Khan A; Bakshi K; Burns LH
Neurobiol Aging; 2017 Jul; 55():99-114. PubMed ID: 28438486
[TBL] [Abstract][Full Text] [Related]
3. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A.
Wang HY; Bakshi K; Frankfurt M; Stucky A; Goberdhan M; Shah SM; Burns LH
J Neurosci; 2012 Jul; 32(29):9773-84. PubMed ID: 22815492
[TBL] [Abstract][Full Text] [Related]
4. Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer's Disease.
Wang HY; Cecon E; Dam J; Pei Z; Jockers R; Burns LH
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762230
[TBL] [Abstract][Full Text] [Related]
5. Increased Aβ
Wang HY; Trocmé-Thibierge C; Stucky A; Shah SM; Kvasic J; Khan A; Morain P; Guignot I; Bouguen E; Deschet K; Pueyo M; Mocaer E; Ousset PJ; Vellas B; Kiyasova V
Alzheimers Res Ther; 2017 Jul; 9(1):54. PubMed ID: 28750690
[TBL] [Abstract][Full Text] [Related]
6. Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development.
Burns LH; Pei Z; Wang HY
Drug Dev Res; 2023 Sep; 84(6):1085-1095. PubMed ID: 37291958
[TBL] [Abstract][Full Text] [Related]
7. Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease.
Burns LH; Wang HY
Neuroimmunol Neuroinflamm; 2017; 4(12):263-271. PubMed ID: 34295950
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease.
Palmqvist S; Insel PS; Stomrud E; Janelidze S; Zetterberg H; Brix B; Eichenlaub U; Dage JL; Chai X; Blennow K; Mattsson N; Hansson O
EMBO Mol Med; 2019 Dec; 11(12):e11170. PubMed ID: 31709776
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
10. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
Aging Clin Exp Res; 2023 Aug; 35(8):1741-1752. PubMed ID: 37264166
[TBL] [Abstract][Full Text] [Related]
11. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
[TBL] [Abstract][Full Text] [Related]
13. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
[TBL] [Abstract][Full Text] [Related]
15. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
[TBL] [Abstract][Full Text] [Related]
16. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
18. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
19. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum.
Gobom J; Benedet AL; Mattsson-Carlgren N; Montoliu-Gaya L; Schultz N; Ashton NJ; Janelidze S; Servaes S; Sauer M; Pascoal TA; Karikari TK; Lantero-Rodriguez J; Brinkmalm G; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Mol Neurodegener; 2022 Dec; 17(1):81. PubMed ID: 36510321
[TBL] [Abstract][Full Text] [Related]
20. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons.
D'Andrea MR; Nagele RG
Curr Pharm Des; 2006; 12(6):677-84. PubMed ID: 16472157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
